- Home
- ENSG vs ROIV Comparison
ENSG vs ROIV Comparison
Compare ENSG & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSG
- ROIV
- Stock Information
- Founded
- ENSG 1999
- ROIV 2014
- Country
- ENSG United States
- ROIV United Kingdom
- Employees
- ENSG N/A
- ROIV N/A
- Industry
- ENSG Hospital/Nursing Management
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ENSG Health Care
- ROIV Health Care
- Exchange
- ENSG Nasdaq
- ROIV Nasdaq
- Market Cap
- ENSG 7.3B
- ROIV 8.4B
- IPO Year
- ENSG 2007
- ROIV N/A
- Fundamental
- Price
- ENSG $143.56
- ROIV $10.76
- Analyst Decision
- ENSG Buy
- ROIV Buy
- Analyst Count
- ENSG 7
- ROIV 4
- Target Price
- ENSG $164.71
- ROIV $17.50
- AVG Volume (30 Days)
- ENSG 398.1K
- ROIV 5.9M
- Earning Date
- ENSG 04-29-2025
- ROIV 05-29-2025
- Dividend Yield
- ENSG 0.17%
- ROIV N/A
- EPS Growth
- ENSG 39.72
- ROIV N/A
- EPS
- ENSG 5.30
- ROIV N/A
- Revenue
- ENSG $4,423,354,000.00
- ROIV $122,585,000.00
- Revenue This Year
- ENSG $16.54
- ROIV N/A
- Revenue Next Year
- ENSG $9.20
- ROIV N/A
- P/E Ratio
- ENSG $27.13
- ROIV N/A
- Revenue Growth
- ENSG 14.81
- ROIV 140.04
- 52 Week Low
- ENSG $115.79
- ROIV $8.73
- 52 Week High
- ENSG $158.45
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- ENSG 73.21
- ROIV 49.33
- Support Level
- ENSG $129.91
- ROIV $10.58
- Resistance Level
- ENSG $133.08
- ROIV $11.77
- Average True Range (ATR)
- ENSG 3.63
- ROIV 0.34
- MACD
- ENSG 1.69
- ROIV -0.05
- Stochastic Oscillator
- ENSG 91.81
- ROIV 15.13
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.